BLEOMYCIN SULFATE
Post-LOEANDAINJECTIONINJECTABLE
Approved
Mar 2019
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
BLEOMYCIN SULFATE by Cipla is mechanism of action although the exact mechanism of action of bleomycin is unknown, available evidence indicates that the main mode of action is the inhibition of dna synthesis with some evidence of lesser inhibition of rna and protein synthesis. First approved in 2019.
Drug data last refreshed Yesterday
Mechanism of Action
Mechanism of Action Although the exact mechanism of action of bleomycin is unknown, available evidence indicates that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. Bleomycin is known to cause single, and to a lesser…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Worked on BLEOMYCIN SULFATE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.